HSIC vs ICUI
Henry Schein vs ICU Medical, Inc. — AI-powered side-by-side comparison
VS
ICUI
ICU Medical, Inc.
48
Watch
| Metric | HSIC | ICUI |
|---|
| AI Score |
67
|
48
|
| Price |
$89.16
|
$181.87
|
| P/E Ratio |
25.77×
|
151.73×
|
| ROE |
12.3%
|
0.0%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
30.3%
|
37.6%
|
| Debt / Equity |
1.21×
|
0.60×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
59.4
|
72.5
|
| Beta |
0.808
|
0.754
|
| Expected Upside |
+0.8%
|
—
|
AI Committee View
Current Innellis committee reasoning for HSIC versus ICUI.
HSIC leads by 19 points.
HSIC scores 67/100 (Buy) versus ICUI at 48/100 (Watch).
HSIC Committee View
75% agreement
4 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is growth rate is decelerating quarter over quarter -- the trend line matters more than the level. The committee is constructive but not yet at full conviction.
Bull Case
- 4 consecutive earnings beats -- consistent execution — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
ICUI Committee View
50% agreement
6 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Growth Analyst remains cautious — revenue declining -10.9% yoy -- this is not a growth story right now. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- P/E of 99.6 is expensive by classic value standards — Value
- ROE of only 2.2% -- cheap may mean cheap for a reason — Value
- Revenue declining -10.9% YoY -- this is not a growth story right now — Growth